GKB Ophthalmics Limited returned to profitability in the financial year ended March 31, 2026, reporting a consolidated net profit of ₹302.72 lakh compared to a net loss of ₹707.92 lakh in the previous year. The turnaround was driven by a 36.8% increase in revenue from operations, which rose to ₹15,130.83 lakh from ₹11,031.86 lakh in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 27, 2026.

On a standalone basis, the company reported a net loss of ₹356.79 lakh for FY26, an improvement from the net loss of ₹610.79 lakh in the previous year. Standalone revenue from operations decreased to ₹2,564.41 lakh from ₹3,274.94 lakh in FY25. The financial performance was impacted by exceptional items amounting to ₹178.99 lakh, primarily due to additional liabilities recognised for gratuity and compensated absences following the notification of new Labour Codes.

Consolidated Financial Performance

The Group’s total income for FY26 stood at ₹15,130.83 lakh, a significant increase from ₹11,031.86 lakh in the prior year. Total expenses for the year were ₹14,635.59 lakh, compared to ₹11,722.79 lakh in FY25. The profit before tax for the year was ₹310.37 lakh, a reversal from the loss before tax of ₹672.62 lakh in the previous year.

For the quarter ended March 31, 2026, the consolidated net profit was ₹111.94 lakh, while revenue from operations stood at ₹2,979.27 lakh. The company reported a basic earnings per share (EPS) of ₹2.42 for FY26, compared to a negative EPS of ₹13.98 in the previous year.

Standalone Financials and Exceptional Items

Standalone total income for FY26 was ₹3,161.22 lakh, down from ₹3,472.16 lakh in the previous year. The company reported a total comprehensive loss of ₹334.88 lakh for the year. The exceptional items of ₹178.99 lakh included ₹120.69 lakh for gratuity liability and ₹28.71 lakh for compensated absences, recognised in the quarter ended March 31, 2026.

Subsidiary and Operational Updates

The Board of Directors of GSV Ophthalmics Private Limited, a material subsidiary, had proposed voluntary winding up as it was not carrying any business. The Holding Company received the total investment of ₹11.70 crore and a residual share of equity of ₹69.72 lakh as deemed dividend by the reporting date. The audited results were subjected to a limited review by the statutory auditors, M S K A & Associates LLP.

GKB Ophthalmics has notified stock exchanges of an upcoming Board of Directors meeting scheduled for Wednesday, May 27, 2026, at its Registered Office located at 16-A, Tivim Industrial Estate, Mapusa, Goa. The notice was issued on May 04, 2026, pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The meeting has been convened to consider and approve the Audited Standalone and Consolidated Financial Results of the company for the quarter and year ended March 31, 2026. The key details of the scheduled board meeting are outlined below:

Trading Window Closure

In connection with the board meeting, GKB Ophthalmics has also disclosed the status of the Trading Window for its equity shares. As per the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the company's equity shares by designated persons had been closed from April 01, 2026. The Trading Window will reopen after the completion of 48 hours from the date of submission of the financial results to the Stock Exchange. This communication has been sent to all Directors and designated employees of the company.

The notice of the board meeting is accessible on the company's official website at www.gkb.net . The announcement was signed by Pooja Dessai née Bicholkar, Company Secretary of GKB Ophthalmics.